In addition, the median age at diagnosis of cancer other than BC or ovarian cancer is higher in the surveillance group than in the BRRM group (both for BRCA1 and BRCA2 mutation carriers), suggesting that with longer follow-up—and thus growing age—the numbers of patients with other tumors could increase. Here, BRCA2 is linked to cancer.